Patients should be monitored closely to ensure that the lowest approved dose of NeoRecormon is used to provide adequate control of the symptoms of anaemia.
Patsiente tuleb hoolikalt jälgida, et tagada NeoRecormon’ i väikseima heakskiidetud annuse kasutamine, mis kindlustab piisava kontrolli aneemianähtude üle.